T-cell Response – Page 7 – Communicable Diseases Research

T-cell recovery and evidence of persistent immune activation 12 months after severe COVID-19

심각한 COVID-19 이후 12개월 동안 T 세포 회복 및 지속적인 면역 활성화의 증거

Article

Published on 2022-08-012022-09-11
Journal: Allergy [Category] COVID19(2023년), SARS, 치료기술, 치료제,

Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination

이종 및 동종 SARS-CoV-2 백신 접종에서 세포 및 체액성 면역 반응의 상호 의존성

Observational Study

Published on 2022-08-012022-09-11
Journal: Allergy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술,

[키워드] Anti-spike Antibody avidity association avidity blood sample Blood samples BNT162b2 booster booster vaccination cellular Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 group healthcare worker Heterologous homologous humoral Humoral and cellular immune responses humoral immune response humoral responses IgG levels immune immune response immune responses immunization interferon interferon-γ nCoV Neutralizing antibodies neutralizing antibody no significant differences Observational cohort study SARS-CoV-2 SARS-CoV-2 vaccination secondary immunization significant difference significant differences Spike protein T-cell T-cell activation T-cell Response T-cell responses unlikely vaccination
[DOI] 10.1111/all.15247 PMC 바로가기 [Article Type] Observational Study

T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine

비활성화 백신의 세 번째 추가 접종 후 돌연변이가 있는 SARS-CoV-2 오미크론 스파이크 에피토프에 대한 T 세포 반응

Article

Published on 2022-08-012022-09-11
Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration Antibody Response Antibody responses booster dose booster vaccination conserved CoronaVac coronavirus dose elicited enhancement Epitopes escape estimate evaluated Impact Inactivated vaccine individual individuals Infection mononuclear cell mononuclear cells Mutation mutations omicron Omicron variant participant Participants PBMCs peptide peptides Peripheral blood Peripheral blood mononuclear cells Protective respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus significantly spike epitope Spike protein Spike proteins stimulate T-cell T-cell activation T-cell Response T-cell responses the SARS-CoV-2 the spike protein Vaccine Vaccines variant virus volunteers weakened were used
[DOI] 10.1002/jmv.27814 PMC 바로가기 [Article Type] Article

Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency

Article

Published on 2022-08-012022-11-15
Journal: Journal of Clinical Immunology [Category] COVID19(2023년), SARS, 진단,

[키워드] anti-S IgG antibody association Autoimmunity B-cells baseline CD19 CD4 CD8 Cellular immune response clinical Cohort common common variable immune deficiency coronavirus disease Coronavirus disease 2019 correlated COVID-19 COVID-19 mRNA vaccines criteria CVID deficiency develop Diagnosis disease dose expression Frequency HCs humoral IgA IgG IgG deficiency IgG subclasse immune Immune profile immunological characteristics impairment investigated memory Moderna Moderna mRNA vaccine mRNA mRNA vaccine naïve neutralization activity OX40 Patient Pfizer-BioNTech Pfizer-BioNTech mRNA vaccine Poor predicted primary antibody primary antibody deficiency response responses SARS-CoV-2 spike protein Selective IgG subclass deficiency significantly lower Specific Specific antibody deficiency. subset T-cell T-cell Response T-cells vaccination Vaccine vaccine response
[DOI] 10.1007/s10875-022-01296-4 PMC 바로가기

Immunogenicity of candidate SARS-CoV-2 DNA vaccines based on the spike protein

스파이크 단백질을 기반으로 한 후보 SARS-CoV-2 DNA 백신의 면역원성

Article

Published on 2022-08-012022-09-12
Journal: Virology [Category] COVID19(2023년), MERS, SARS, 진단,

Response to mRNA COVID-19 vaccination in three XLA patients

Short communication

Published on 2022-08-012022-10-05
Journal: Vaccine [Category] 변종,

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

일본 참가자의 S-268019-b 또는 BNT162b2 추가 용량의 면역원성과 안전성: 2/3상, 무작위, 관찰자 맹검, 비열등성 연구의 중간 보고서

Clinical Trial

Published on 2022-07-302022-09-11
Journal: Vaccine [Category] MERS, 변종, 임상, 진단,

[키워드] 95% CI analyzed Anti-spike antibodies BNT162b2 booster booster dose Booster vaccine clinical clinical trial co-primary endpoint co-primary endpoints COVID-19 Delta elicited fatigue Fever geometric mean geometric mean titer GMT GMT ratio immunization immunogenicity Immunoglobulin Immunoglobulin G injection Injection-site pain Interim report Interim result interim results Japanese Live virus MOST myalgia neutralization test Neutralizing antibodies neutralizing antibody observer observer-blinded omicron P-value participant phase 2/3 produced pseudovirus Randomized reactogenicity recombinant Recombinant spike protein regimen reported robust Safe SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Spike protein subgroups T-cell Response Vaccine variant
[DOI] 10.1016/j.vaccine.2022.06.032 PMC 바로가기 [Article Type] Clinical Trial

Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials

동종 또는 이종 체계에서 항 SARS CoV-2 백신 SOBERANA 02의 안전성 및 면역원성: 공개 라벨 임상 1상 및 2a상 임상 시험

Clinical Trial

Published on 2022-07-292022-09-11
Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] adaptive adverse event Anti-RBD IgG Antigen clinical trial clinical trials conjugate Conjugate vaccine COVID-19 COVID-19 vaccine D614G delta variant dose doses elicited ELISA evaluate evaluated frequencies Frequency hACE2 Heterologous heterologous immunization Heterologous immunization scheme homologous homologous or heterologous IgG IgG ELISA IIa immune response immune responses immunogenic immunogenicity Immunological response Interaction local pain molecular neutralization neutralized Neutralizing antibodies neutralizing antibody Open-label outcome Panel performed phase Phase I phase IIa Primary outcome progressed protocol protocols RBD receive receiving reduction reported Safe Safety SARS-CoV-2 secondary outcome selected Specific T-cell response subjects Subunit vaccine T-cell T-cell Response T-cells Tetanus tetanus toxoid trials Vaccine variant Volunteer volunteers
[DOI] 10.1016/j.vaccine.2022.05.082 PMC 바로가기 [Article Type] Clinical Trial

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria

Schwaz/Austria 지역에서 BNT162b2를 사용한 SARS-CoV-2에 대한 신속한 대량 백신 접종 후 면역 반응의 6개월 추적

Article

Published on 2022-07-272022-09-11
Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] age Analysis antibody Antibody Response B-cell response B.1.351 Beta BNT162b2 carried correlated COVID-19 detect District enrolment evaluate immune response immune responses Infection mass mass vaccination natural infection new SARS-CoV-2 no correlation outbreak participant participated preserved provide Rapid reduction in response robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 infections second dose Seropositivity Serum level serum levels specific antibodies spring study participant subject Support T cell T cell response T cell responses T-cell Response the District the SARS-CoV-2 vaccination variant waned was measured
[DOI] 10.3390/v14081642 PMC 바로가기 [Article Type] Article

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave

첫 번째 대유행 기간 동안 COVID-19 사례의 가정 접촉에서 경미한 COVID-19 환자의 조정된 타고난 및 T 세포 면역 반응

Article

Published on 2022-07-272022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료기술, 치료법,

[키워드] absence Alpha anti-N antibodies anti-RBD antibody B-cell cell-mediated response Concordance Contact COVID-19 COVID-19 case COVID-19 cases Cycle threshold value cytokine detectable early immune response early immune responses ELISA enrolled evaluated Factor Follow-up greater high accuracy household household contact household contacts IFN-α IFN-γ IL-1ra IL-1β IL-9 immune responses immunofluorescence Immunopathogenesis indirect immunofluorescence individual innate response interferon interferon-alpha Interferon-alpha (IFN-α) Interferon-gamma Interferon-gamma (IFN-γ) release assay (IGRA) IP-10 MCP-1 membrane mild COVID-19 patient MIP-1β moderate Nasopharyngeal swab Neutralizing antibodies nucleocapsid pandemic peptide peptide pools plasma plasma samples positive positive swab Proteins RANTES RBD reported response returned RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 swab screened Seroconversion serological serological response significant negative correlation Spike protein stimulated subject Surveillance Swab Swab test swabs T-cell T-cell immune response T-cell Response T-cell specific virus Whole blood
[DOI] 10.3389/fimmu.2022.920227 PMC 바로가기 [Article Type] Article